منابع مشابه
Clinical experience with cinacalcet HCl.
Secondary hyperparathyroidism (SHPT) is associated with parathyroid gland hyperplasia, increased parathyroid hormone (PTH) production and secretion, disturbed bone and mineral metabolism, soft tissue calcification and an increased risk of death. The condition is an almost universal complication of end-stage renal disease (ESRD) and currently is managed by treatment with phosphate binders and vi...
متن کاملPharmacodynamics of the type II calcimimetic compound cinacalcet HCl.
Calcimimetic compounds, which activate the parathyroid cell Ca(2+) receptor (CaR) and inhibit parathyroid hormone (PTH) secretion, are under experimental study as a treatment for hyperparathyroidism. This report describes the salient pharmacodynamic properties, using several test systems, of a new calcimimetic compound, cinacalcet HCl. Cinacalcet HCl increased the concentration of cytoplasmic C...
متن کاملSuccessful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
Secondary hyperparathyroidism is a common complication for patients with end-stage renal disease (ESRD). When it progresses, it is associated with morbidity and mortality [1]. Phosphate binders and vitamin D can be used to prevent the progression of secondary hyperparathyroidism. However, these conservative treatments often fail to control severe hyperparathyroidism. In such cases, parathyroide...
متن کاملPersistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl.
BACKGROUND Hyperparathyroidism is uncommon in adolescence and is more likely to persist after parathyroidectomy than in adults. Cinacalcet HCl is a new calcimimetic that has been used successfully for the treatment of primary and secondary hyperparathyroidism in adults, but its use in adolescents has not been reported. CASE A 16 year-old male presented with hypercalcemia that had persisted fo...
متن کاملLong-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
BACKGROUND Patients with secondary hyperparathyroidism often require therapy that provides long-term control of parathyroid hormone concentrations without increasing calcium and phosphorus concentrations. Cinacalcet modulates the calcium-sensing receptor on the parathyroid gland to reduce secretion of parathyroid hormone and lower serum calcium, phosphorus and calcium-phosphorus product in haem...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Swiss Medical Forum ‒ Schweizerisches Medizin-Forum
سال: 2007
ISSN: 1424-4020,1424-3784
DOI: 10.4414/smf.2007.06100